PROSTVAC™ paper published in Journal of Clinical Oncology
Not for release, publication or distribution, directly or indirectly in or into Australia, Canada, Japan or the United States
This announcement does not constitute or form part of an offer to sell or the solicitation of an offer to buy the securities of Bavarian Nordic A/S (the "Securities") in Australia, Canada, Japan or the United States or in any other jurisdiction. The Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The issuer of the Securities has not registered, and does not intend to register, any portion of the Offering in the United States or in any jurisdiction outside Denmark and the United Kingdom, and does not intend to conduct a public offering of the Securities in the United States or in any jurisdiction outside Denmark and the United Kingdom. Copies of this announcement are not being made and may not be distributed or sent into Australia, Canada, Japan or the United States.
Kvistgård, Denmark, January 26, 2010 -Bavarian Nordic A/S (OMX: BAVA) announced today that a PROSTVAC™ paper has been published in the peer-reviewed Journal of Clinical Oncology (JCO), the official journal of ASCO (American Society of Clinical Oncology).
As announced in the prospectus dated 8 January 2010 regarding the ongoing rights issue, Bavarian Nordic submitted its article to the journal in 2009 with the expected publication in the first half of 2010.
The paper titled: "Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer" has been published ahead of print on JCO's website:
The paper is based on the previously reported Phase II study, showing a significant longer median survival (8.5 months) in men with advanced prostate cancer.
Anders Hedegaard, President & CEO of Bavarian Nordic said: "We are delighted that our PROSTVAC™ data has been accepted for publication in Journal of Clinical Oncology, one of the most prominent peer-reviewed oncology journals. This is indeed a major recognition of the scientific potential of the vaccine and highly supports the further development and our ongoing preparations for the Phase III trials with PROSTVAC™."
PROSTVAC™ is a therapeutic vaccine moving into late stage clinical development that has the potential to extend the lives of people with advanced prostate cancer. Administered subcutaneously, it induces a specific, targeted immune response that attacks prostate cancer cells. Conventional chemotherapy currently used to treat prostate cancer has limited survival rates and is often associated with numerous side effects. In contrast, PROSTVAC™ has the potential to extend survival with improved quality of life. PROSTVAC™ is being developed in collaboration with the National Cancer Institute under a Cooperative Research and Development Agreement with Bavarian Nordic's U.S.-based subsidiary, BN ImmunoTherapeutics.
In clinical trials to date PROSTVAC™ and related PSA containing poxviral vaccines have been investigated and optimised in more than 500 patients for 10 years.